冠状动脉放射性血管病:最新综述
本文综述了放射性相关冠状动脉疾病(RACAD)的独特生物学与临床特征。电离辐射通过自由基生成和促炎级联激活导致内皮功能障碍和加速动脉粥样硬化。RACAD风险取决于放疗剂量、冠状动脉与放疗野的邻近程度以及患者因素。临床可早期(1-2年)或经5-20年潜伏期后出现,症状常被癌症相关症状掩盖。诊断与管理遵循标准冠心病指南但需整合癌症特异性考量,强调精准放疗和心脏屏蔽的一级预防,并指出多个知识缺口。
要点
- RACAD是胸部放疗后 distinct 的冠心病形式,风险与放疗剂量和冠状动脉邻近放疗野相关。
- 临床可早期(1-2年)或经5-20年潜伏期后出现,症状常被癌症相关疲劳等掩盖。
- 诊断管理遵循标准冠心病指南但需整合癌症特异性因素,一级预防强调精准放疗和心脏屏蔽。
核心结论
- RACAD是具有独特生物学和临床特征的冠心病形式,存在多个关键知识缺口。
- 一级预防至关重要,强调精准放疗技术改进冠状动脉剂量测定和心脏屏蔽。
研究设计与样本
- 本文为综述,系统汇总了RACAD的生物学、临床特征、风险因素、诊断管理及知识缺口。
主要发现
- 电离辐射诱导自由基生成和促炎级联激活,导致内皮功能障碍和加速动脉粥样硬化。
- RACAD风险由放疗因素(辐射剂量、冠状动脉与放疗野邻近程度)和患者因素(年轻年龄、更高基线心血管风险、同步心脏毒性全身治疗)共同决定。
- 临床可早期出现(1-2年内),尤其在心脏辐射剂量较高的患者(如肺癌或食管癌),或经5-20年潜伏期后出现于较低心脏剂量暴露者(如左侧乳腺癌)。
- RACAD症状可能因与治疗相关疲劳、肺部疾病或竞争性肿瘤症状重叠而在癌症幸存者中被低估。
关键数值与推荐
- 诊断和管理一般遵循标准冠心病指南,同时纳入癌症特异性考量(如计划肿瘤手术、出血风险、放疗后并发症如内乳动脉闭锁、全身癌症治疗的心脏毒性效应)。
临床怎么用
- 对胸部放疗患者应评估冠状动脉辐射剂量和心脏屏蔽情况,并纳入癌症特异性因素进行风险管理。
- 对癌症幸存者需警惕RACAD症状,避免被治疗相关疲劳或肺部疾病掩盖。
- 诊断和治疗遵循标准冠心病指南,但需整合计划肿瘤手术、出血风险、放疗后并发症和全身治疗心脏毒性等癌症特异性考量。
局限性
- 知识缺口包括:当代三维适形放疗技术的长期结局、基于冠状动脉剂量测定的验证性癌症特异性风险预测模型、最佳监测方案、靶向分子药物治疗、经皮与外科管理RACAD的风险分析。
- 需要前瞻性研究开发癌症和剂量测定特异性风险计算器、验证心脏保护干预措施并改善多学科心脏肿瘤协作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiation-associated coronary artery disease (RACAD) is a distinct form of coronary artery disease with several specific biological and clinical aspects as well as key knowledge gaps. RACAD is prevalent in patients with cardiac exposure to radiotherapy. As radiotherapy is integral to the effective treatment of many thoracic malignancies, improved long-term survivorship is coupled with increased risk for RACAD. Ionizing radiation induces free radical generation and activation of proinflammatory cascades, leading to endothelial dysfunction and accelerated atherosclerosis. Risks for RACAD are determined both by radiotherapy, including the radiation dose and the proximity of coronary arteries to the radiotherapy field, and by patient-specific factors, such as younger age, higher baseline cardiovascular risk, and concurrent cardiotoxic systemic therapies. Importantly, radiotherapy delivery is highly individualized on the basis of tumor location and treatment strategy, resulting in heterogeneous coronary exposure to radiation and patient-to-patient variability. Clinical presentation may occur early, within 1 to 2 years, especially in patients with higher cardiac radiation doses (eg, lung or esophageal cancer), or after a latency period of 5 to 20 years with lower cardiac dose radiation exposure (eg, left-sided breast cancer). Patients generally present with symptoms similar to conventional coronary artery disease. However, RACAD symptoms may be underrecognized in cancer survivors due to overlapping treatment-related fatigue, pulmonary disease, or competing oncologic symptoms. Diagnosis and management generally follow standard coronary artery disease guidelines while incorporating cancer-specific considerations, such as planned oncologic surgeries, bleeding risk, postradiotherapy complications such as atretic internal mammary arteries, and cardiotoxic effects of systemic cancer therapies. Primary prevention of RACAD is critical, emphasizing advances in precision radiotherapy, including delivery techniques with improved coronary dosimetry, and cardiac shielding. Key knowledge gaps include understanding long-term outcomes with contemporary 3-dimensional conformal radiotherapy techniques, validated cancer-specific risk prediction models on the basis of coronary dosimetry, optimal surveillance protocols, targeted molecular pharmacotherapies, and risk analysis of percutaneous versus surgical management of RACAD. Prospective studies are needed to develop cancer- and dosimetry-specific risk calculators, validating cardioprotective interventions, and improving multidisciplinary cardio-oncology collaboration to optimize early detection of RACAD and timely intervention in the growing population of cancer survivors.
引用
- Xia J, Kim J, Sharma A, et al. Radiation Vasculopathy of the Coronary Arteries: State-of-the Art Review. Circulation. 2026. PMID: 42895999. doi:10.1161/CIRCULATIONAHA.126.079541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。